Evidence map›Paper›PMID 29747676›Full record

ArticleDiagnostic pathology2018

Epithelioid cell histiocytoma with SQSTM1-ALK fusion: a case report.

Ryuko Nakayama, Yuki Togashi, Satoko Baba, Yo Kaku, Yuki Teramoto, Takaki Sakurai, Hironori Haga, Kengo Takeuchi

Open access · goldAbstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Superficial ALK-rearranged myxoid spindle cell neoplasm: a cutaneous soft tissue tumor with distinctive morphology and immunophenotypic profile.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ryuko NakayamaDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
Yuki TogashiPathology Project for Molecular Targets, the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Satoko BabaPathology Project for Molecular Targets, the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yo KakuDepartment of Dermatology, Kyoto University Hospital, Kyoto, Japan.
Yuki TeramotoDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
Takaki SakuraiDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
Hironori HagaDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan. haga@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0003-4322-9561
Kengo TakeuchiPathology Project for Molecular Targets, the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kyoto University Hospital · JPJapanese Foundation For Cancer Research · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpithelioid cell histiocytoma (ECH), which is also known as epithelioid benign fibrous histiocytoma, has been classified as a rare variant of fibrous histiocytoma (FH). However, the recent detection of ALK protein expression and/or ALK gene rearrangement in ECH suggests that it might be biologically different from conventional FH. CASE PRESENTATION: A 27-year-old male presented with nodule on his left foot, which had been present for 5 years. A macroscopic examination revealed an exophytic, hyperkeratotic nodule on the dorsum of the left foot. Tumorectomy was performed, and a microscopic examination showed a subepidermal lesion composed of sheets of tumor cells with oval to round nuclei and ill-defined eosinophilic cytoplasm. The tumor cells were diffusely positive for factor XIIIa and ALK, but were negative for AE1/AE3 keratin, alpha-smooth muscle actin, CD30, CD34, CD68, PU.1, melan A, MITF, and S-100 protein. ALK immunostaining showed a diffuse cytoplasmic staining pattern. ALK fluorescence in situ hybridization demonstrated break-apart signals, which was suggestive of ALK rearrangement. A 5'-rapid amplification of cDNA ends assay detected SQSTM1-ALK fusion, in which exon 5 of the SQSTM1 gene was fused to exon 20 of the ALK gene. The patient was free from recurrence and distant metastasis at the 1-year of follow-up.

conclusionWe were able to demonstrate the SQSTM1-ALK fusion gene in ECH. Practically, detecting immunopositivity for ALK and appropriate cell-lineage markers are the key to diagnosing ECH.

Indexed as

AdultAnaplastic Lymphoma KinaseHistiocytoma, Benign FibrousHumansMaleOncogene FusionReceptor Protein-Tyrosine KinasesSequestosome-1 ProteinSkin NeoplasmsALK protein, humanAnaplastic Lymphoma KinaseReceptor Protein-Tyrosine KinasesSequestosome-1 ProteinSQSTM1 protein, humanALK gene rearrangementEpithelioid cell histiocytomaFibrous histiocytomaSQSTM1-ALK gene fusion

Identifiers

PMID29747676
PMCPMC5946425
OpenAlexW2806460616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.